Sentinel Lymph Node Biopsy in Thin Cutaneous Melanoma: A Systematic Review and Meta-Analysis

Annals of Surgical Oncology

Volumn 23, Issue 13, 2016, Pages 4178-4188

  Cordeiro, Erin ^a   Gervais, Mai Kim ^b   Shah, Prakesh S ^c,d   Look Hong, Nicole J ^b,e   Wright, Frances C ^b,e  

^a UNIVERSITY OF OTTAWA   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c MOUNT SINAI HOSPITAL   (Canada)

^d UNIVERSITY OF TORONTO   (Canada)

^e SUNNYBROOK RESEARCH INSTITUTE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CANCER PATIENT; CUTANEOUS MELANOMA; HUMAN; IMMUNOHISTOCHEMISTRY; MANTEL HAENSZEL TEST; META ANALYSIS; OUTCOME ASSESSMENT; PREDICTION; QUALITY CONTROL; SENTINEL LYMPH NODE BIOPSY; SYSTEMATIC REVIEW; TUMOR ASSOCIATED LEUKOCYTE; TUMOR VOLUME; LYMPH NODE; LYMPH NODE METASTASIS; MELANOMA; MITOSIS INDEX; PATHOLOGY; PATIENT SELECTION; RISK FACTOR; SECONDARY; SKIN TUMOR;

HUMANS; LYMPH NODES; LYMPHATIC METASTASIS; MELANOMA; MITOTIC INDEX; PATIENT SELECTION; RISK FACTORS; SENTINEL LYMPH NODE BIOPSY; SKIN NEOPLASMS; TUMOR BURDEN;

EID: 84959353653     PISSN: 10689265     EISSN: 15344681     Source Type: Journal    
DOI: 10.1245/s10434-016-5137-z     Document Type: Article

References (87)

1. World Health Organization. GLOBOCAN 2012: estimated cancer incidence, mortality and prevalence worldwide in 2012. http://globocan.iarc.fr/Pages/fact_sheets_cancer.aspx (2012). Accessed 15 Mar 2015.
2. Nikolaou, V, Stratigos AJ. Emerging trends in the epidemiology of melanoma. Br J Dermatol. 2014;170(1):11–9.
3. Gimotty PA, et al. Thin primary cutaneous malignant melanoma: a prognostic tree for 10-year metastasis is more accurate than American Joint Committee on Cancer staging. J Clin Oncol. 2004;22(18):3668–76.
4. McKinnon JG, et al. Prognosis for patients with thin cutaneous melanoma: long-term survival data from New South Wales Central Cancer Registry and the Sydney Melanoma Unit. Cancer. 2003;98(6):1223–31.
5. Balch CM, et al. Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol. 2009;27(36):6199–206.
6. Valsecchi ME, et al. Lymphatic mapping and sentinel lymph node biopsy in patients with melanoma: a meta-analysis. J Clin Oncol. 2011;29(11):1479–87.
7. Morton DL, et al. Sentinel-node biopsy or nodal observation in melanoma. N Engl J Med. 2006;355(13):1307–17.
8. Wrightson WR, et al. Complications associated with sentinel lymph node biopsy for melanoma. Ann Surg Oncol. 2003;10(6):676–80.
9. Coit DG, et al. Melanoma, version 4.2014: featured updates to the NCCN guidelines. JNCCN J Natl Compr Cancer Netw. 2014;12(5):621–9.
10. Wong SL, et al. Sentinel lymph node biopsy for melanoma: American Society of Clinical Oncology and Society of Surgical Oncology Joint Clinical Practice guideline. J Clin Oncol. 2012;30(23):2912–8.
11. Dummer R, et al. Cutaneous melanoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2012;23(7):vii86–91.
12. Roberts DL, et al. U.K. guidelines for the management of cutaneous melanoma. Br J Dermatol. 2002;146(1):7–17.
13. Bartlett EK, et al. Clark level risk stratifies patients with mitogenic thin melanomas for sentinel lymph node biopsy. Ann Surg Oncol. 2014;21(2):643–9.
14. Karakousis GC, et al. Predictors of regional nodal disease in patients with thin melanomas. Ann Surg Oncol. 2006;13(4):533–41.
15. Kaur C, et al. The correlation of regression in primary melanoma with sentinel lymph node status. J Clin Pathol. 2008;61(3):297–300.
16. Kesmodel SB, et al. Mitotic rate as a predictor of sentinel lymph node positivity in patients with thin melanomas. Ann Surg Oncol. 2005;12(6):449–58.
17. Yonick DV, et al. Predictors of positive sentinel lymph node in thin melanoma. Am J Surg. 2011;201(3):324–7 (Discussion 327–8).
18. Ribas A, et al. Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial. Lancet Oncol. 2015;16(8):908–18.
19. Larkin J, et al. Vemurafenib in patients with BRAF(V600) mutated metastatic melanoma: an open-label, multicentre, safety study. Lancet Oncol. 2014;15(4):436–44.
20. Chapman PB, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med. 2011;364(26):2507–16.
21. Moher D, et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009;6(7):e1000097.
22. Wells GA. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp (2014). Accessed 4 July 2014.
23. Han D, et al. Clinicopathologic predictors of sentinel lymph node metastasis in thin melanoma. J Clin Oncol. 2013;31(35):4387–93.
24. Jaber JJ, et al. Evolving treatment strategies in thin cutaneous head and neck melanoma: one institution’s experience. Head Neck. 2011;33(1):7–12.
25. Balch CM, et al. Age as a predictor of sentinel node metastasis among patients with localized melanoma: an inverse correlation of melanoma mortality and incidence of sentinel node metastasis among young and old patients. Ann Surg Oncol. 2014;21(4):1075–81.
26. Cafiero F, et al. The role of sentinel lymph node biopsy in patients with stage I/II cutaneous melanoma: the clinical experience at the National Cancer Research Institute of Genoa, Italy. Tumori. 2002;88(3):S55–6.
27. Doumas A, et al. Is 0.75-mm Breslow thickness the right cut-off point for performing sentinel node biopsy in patients with melanoma? Eur J Nucl Med Mol Imaging. 2010;37:S442–3.
28. Murali R, et al. Sentinel lymph node biopsy in patients with thin primary cutaneous melanoma. Ann Surg. 2012;255(1):128–33.
29. Nahabedian MY, Tufaro AP, Manson PN. Sentinel lymph node biopsy for the T1 (thin) melanoma: is it necessary? Ann Plast Surg. 2003;50(6):601–6.
30. Venna SS, et al. Analysis of sentinel lymph node positivity in patients with thin primary melanoma. J Am Acad Dermatol. 2013;68(4):560–7.
31. Sperry SM, Charlton ME, Pagedar NA. Association of sentinel lymph node biopsy with survival for head and neck melanoma: survival analysis using the SEER database. JAMA Otolaryngol Head Neck Surg. 2014;140(12):1101–9.
32. Higgins JP, et al. Measuring inconsistency in meta-analyses. BMJ. 2003;327(7414):557–60.
33. Review Manager (2014) The Nordic cochrane center. The Cochrane Collaboration, Copenhagen.
34. Wallace BC, et al. OpenMetaAnalyst: closing the gap between methodologists and end-users: R as a computational back-end. J Stat Softw 2012;49:1–15.
35. McMasters KM, et al. Lessons learned from the Sunbelt Melanoma Trial. J Surg Oncol. 2004;86(4):212–23.
36. Rossi CR, et al. Number of excised lymph nodes as a quality assurance measure for lymphadenectomy in melanoma. JAMA Surg. 2014;149(7):700–6.
37. Rossi CR, et al. The number of excised lymph nodes is associated with survival of melanoma patients with lymph node metastasis. Ann Oncol. 2014;25(1):240–6.
38. Mitteldorf C, et al. Sentinel node biopsy improves prognostic stratification in patients with thin (pT1) melanomas and an additional risk factor. Ann Surg Oncol. 2014;21(7):2252–8.
39. Warycha M, et al. Metaanalysis of sentinel lymph node positivity in thin melanoma (<1 mm). J Am Acad Dermatol. 2009;1:AB10.
40. Cascinelli N, et al. Sentinel lymph node biopsy in cutaneous melanoma: the WHO Melanoma Program experience. Ann Surg Oncol. 2000;7(6):469–74.
41. Ishihara T, et al. Sentinel lymph nodes study in 30 cases of melanoma. J Dermatol. 2001;28(7):347–52.
42. Nguyen CL, et al. Melanoma thickness and histology predict sentinel lymph node status. Am J Surg. 2001;181(1):8–11.
43. Muller S, et al. No indication for performing sentinel node biopsy in melanoma patients with a Breslow thickness of less than 0.9 mm. Melanoma Res. 2001;11(3):303–7.
44. Agnese DM, et al. Cost-effectiveness of sentinel lymph node biopsy in thin melanomas. Surgery. 2003;134(4):542–8.
45. Evans HL, et al. Lymphoscintigraphy and sentinel node biopsy accurately stage melanoma in patients presenting after wide local excision. Ann Surg Oncol. 2003;10(4):416–25.
46. Jacobs IA, et al. Role of sentinel lymph node biopsy in patients with thin (<1 mm) primary melanoma. Ann Surg Oncol. 2003;10(5):558–61.
47. Lowe JB, et al. Sentinel lymph node biopsy in patients with thin melanoma. Arch Dermatol. 2003;139(5):617–21.
48. Nowecki ZI, et al. Sentinel lymph node biopsy in melanoma patients with clinically negative regional lymph nodes: one institution’s experience. Melanoma Res. 2003;13(1):35–43.
49. Oliveira Filho RS, et al. Vertical growth phase and positive sentinel node in thin melanoma. Braz J Med Biol Res. 2003;36(3):347–50.
50. Rousseau DL Jr, et al. Revised American Joint Committee on Cancer staging criteria accurately predict sentinel lymph node positivity in clinically node-negative melanoma patients. Ann Surg Oncol. 2003;10(5):569–74.
51. Chakera AH, et al. Sentinel node biopsy for melanoma: a study of 241 patients. Melanoma Res. 2004;14(6):521–6.
52. Moehrle M, et al. Micrometastasis of a sentinel lymph node in cutaneous melanoma is a significant prognostic factor for disease-free survival, distant-metastasis-free survival, and overall survival. Dermatol Surg. 2004;30(10):1319–28.
53. Sondak VK, et al. Mitotic rate and younger age are predictors of sentinel lymph node positivity: lessons learned from the generation of a probabilistic model. Ann Surg Oncol. 2004;11(3):247–58.
54. Stitzenberg KB, et al. Indications for lymphatic mapping and sentinel lymphadenectomy in patients with thin melanoma (Breslow thickness ≤1.0 mm). Ann Surg Oncol. 2004;11(10):900–6.
55. Berk DR, et al. Sentinel lymph node biopsy for cutaneous melanoma: the Stanford experience, 1997–2004. Arch Dermatol. 2005;141(8):1016–22.
56. Puleo CA, et al. Sentinel node biopsy for thin melanomas: which patients should be considered? Cancer Control. 2005;12(4):230–5.
57. Rex J, et al. Single-institution experience in the management of patients with clinical stage I and II cutaneous melanoma: results of sentinel lymph node biopsy in 240 cases. Dermatol Surg. 2005;31(11 Pt 1):1385–93.
58. Roka F, et al. Sentinel node status in melanoma patients is not predictive for overall survival upon multivariate analysis. Br J Cancer. 2005;92(4):662–7.
59. Cascinelli N, et al., Sentinel and nonsentinel node status in stage IB and II melanoma patients: two-step prognostic indicators of survival. J Clin Oncol. 2006;24(27):4464–71.
60. Lock-Andersen J, et al. Sentinel node biopsy in cutaneous melanoma. Scand J Plast Reconstr Surg Hand Surg. 2006;40(1):24–31.
61. Ranieri JM, et al. The prognostic importance of sentinel lymph node biopsy in thin melanoma. Ann Surg Oncol. 2006;13(7):927–32.
62. Vaquerano J, et al. American Joint Committee on Cancer clinical stage as a selection criterion for sentinel lymph node biopsy in thin melanoma. Ann Surg Oncol. 2006;13(2):198–204.
63. Wong SL, et al. Results of sentinel lymph node biopsy in patients with thin melanoma. Ann Surg Oncol. 2006;13(3):302–9.
64. Cecchi R, et al. Sentinel lymph node biopsy in patients with thin melanomas. J Dermatol. 2007;34(8):512–5.
65. Koskivuo I, et al. Sentinel lymph node biopsy in cutaneous melanoma: a case-control study. Ann Surg Oncol. 2007;14(12):3566–74.
66. Starz H, Balda BR. Benefit of sentinel lymphadenectomy for patients with nonulcerated cutaneous melanomas in the Breslow range between 0.76 and 1 mm: a follow-up study of 148 patients. Int J Cancer. 2007;121(3):689–93.
67. Mattsson J, et al. Sentinel node biopsy in malignant melanoma: Swedish experiences 1997–2005. Acta Oncol. 2008;47(8):1519–25.
68. Roulin D, et al. Prognostic value of sentinel node biopsy in 327 prospective melanoma patients from a single institution. Eur J Surg Oncol. 2008;34(6):673–9.
69. Wright BE, et al. Importance of sentinel lymph node biopsy in patients with thin melanoma. Arch Surg. 2008;143(9):892–9 (Discussion 899–900).
70. Aviles-Izquierdo JA, Lazaro-Ochaita P. Sentinel node biopsy as a prognostic factor in cutaneous melanoma. Actas Dermo-Sifiliogr. 2009;100(6):486–92.
71. Testori A, et al. Clinical considerations on sentinel node biopsy in melanoma from an Italian multicentric study on 1313 patients (SOLISM-IMI). Ann Surg Oncol. 2009;16(7):2018–27.
72. Ellis MC, et al. Sentinel lymph node staging of cutaneous melanoma: predictors and outcomes. Am J Surg. 2010;199(5):663–8.
73. Kunte C, et al. Prognostic factors associated with sentinel lymph node positivity and effect of sentinel status on survival: an analysis of 1049 patients with cutaneous melanoma. Melanoma Res. 2010;20(4):330–7.
74. Socrier Y, et al. Histological regression in primary melanoma: not a predictor of sentinel lymph node metastasis in a cohort of 397 patients. Br J Dermatol. 2010;162(4):830–4.
75. Vermeeren L, et al. Sentinel lymph node biopsy in patients with thin melanoma: occurrence of nodal metastases and its prognostic value. Eur J Dermatol. 2010;20(1):30–34.
76. Andtbacka RH, et al. Sentinel lymph node biopsy for melanoma in pregnant women. Ann Surg Oncol. 2013;20(2):689–96.
77. Rughani MG, et al. Sentinel lymph node biopsy in melanoma: the Oxford ten year clinical experience. J Plast Reconstr Aesth Surg. 2011;64(10):1284–90.
78. Han D, et al. Sentinel node biopsy is indicated for thin melanomas >0.76 mm. Ann Surg Oncol. 2012;19(11):3335–42.
79. Hinz T, et al. Prognostic value of sentinel lymph node biopsy in 121 low-risk melanomas (tumour thickness <1.00 mm) on the basis of a long-term follow-up. Eur J Nucl Med Mol Imaging. 2012;39(4):581–8.
80. Chu VH, et al. Impact of the 2009 (7th Edition) AJCC melanoma staging system in the classification of thin cutaneous melanomas. BioMed Res Int. 2013;2013:898719.
81. Cooper C, et al. A 10-year, single-institution analysis of clinicopathologic features and sentinel lymph node biopsy in thin melanomas. J Am Acad Dermatol. 2013;69(5):693–9.
82. Egger ME, et al. Outcomes and prognostic factors in superficial spreading melanoma. Am J Surg. 2013;206(6):861–8.
83. Mori M, et al. Clinicopathologic analysis of 66 Japanese thin melanomas with metastasis of sentinel or regional lymph node. J Cutan Pathol. 2013;40(12):1027–34.
84. Mozzillo N, et al. Sentinel node biopsy in thin and thick melanoma. Ann Surg Oncol. 2013;20(8):2780–6.
85. van den Broek FJ, et al. Sentinel lymph node biopsy for cutaneous melanoma: results of 10 years’ experience in two regional training hospitals in the Netherlands. Int J Clin Oncol. 2013;18(3):428–34.
86. Botella-Estrada R, et al. Correlation of histologic regression in primary melanoma with sentinel node status. JAMA Dermatol. 2014;150(8):828–35.
87. Voit, C.A., et al., Ultrasound-guided fine needle aspiration cytology as an addendum to sentinel lymph node biopsy can perfect the staging strategy in melanoma patients. Eur J Cancer (Oxford, England: 1990). 2014;50(13):2280–8.